To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Growing Prevalence of Cardiovascular Diseases

The rapid increase in the spread of cardiovascular diseases (CVDs) globally acts as a major stimulant within the heparin market. According to World Health Organization, by 2023, over 17.9 million people died from CVDs each year, making it the number one cause of death in the world (World Health Organization). This is owing to its excellent anticoagulation characteristics; it is quite useful for treating these ailments mostly during surgeries or with high vulnerability to thrombosis. It stops harmful clots from forming that can lead to stroke and heart attack. The instances of its use are rising because of increasing cases of CVDs such as coronary artery disease and peripheral artery disease.

Heparin demand will further be boosted due to these conditions affecting aging populations more than any other age group. CVDs accounted for 32% of all global deaths in 2023, with 85% attributable to heart attacks and strokes. The cases of coronary heart disease (CHD) alone in India are estimated at 31.8 million individuals which is ten times higher than what was recorded over four decades ago. Also, there were revealed rates of VTE in patients hospitalized with COVID-19 at 40% and up to 9.5% without ultrasound screening.

Further innovations like low molecular weight heparins (LMWH) have made drug delivery systems safer and easier during administration hence attracting more physicians and patients alike towards heparin product offerings. L.M.W.H is commonly used for prevention and treatment purposes for deep vein thrombosis as well as pulmonary embolism in the heparin market. North American region currently has the largest share in heparin market worldwide since prevalence rate CVDs is high accompanied by presence key players in this market segment Asia Pacific on the other hand holds significant potential for growth due increased healthcare spending, improving healthcare infrastructure coupled with large population size among others reasons.

Trend: Rise of Biosimilar Heparin Products

Trend towards production and release of biosimilar heparin products has been on the rise in recent years. Biosimilars are biologics that are highly alike to an already approved reference product with no clinically meaningful differences. They have similar therapeutic benefits as the original but at a considerably lower price. For example, introduction of biosimilar enoxaparin has caused treatment costs reduction by about 30% in some markets. The expiry of patents for major heparin drugs means that numerous pharmaceutical companies worldwide operating in this market have heavily invested into research and development (R&D) aimed at producing biosimilar versions.

This trend increases competition on the heparin market t and broadens access to lifesaving anticoagulant therapy to more patients, particularly those from low-to-middle income countries where affordability limits access. This is evident from findings indicating that by increasing patient accessibility by up to 40%, India has raised its availability of biosimilar heparin. The extent of acceptance among healthcare professionals and patients will largely determine the market uptake of these products despite their potentiality as a solution towards bringing down drug prices. Indeed, some biologics’ market shares in European Union are even more than fifty percent for biosimilars.

Furthermore, the global biosimilar market is expected to grow with a CAGR of 17.6% until it reaches $1.3 Trillion valuation by 2032 In USA alone, FDA had given nod to 29 such versions as at 2023 with many more awaiting approvals in pipeline. Some successful examples include Inhixa, Thorinane and Neoparin as evidence has shown they exhibit similar efficacy as well as safety profiles compared to their generic counterparts thereby boosting their uptake rates among consumers (IMS Health) in the global heparin market. As time goes on, there will be increased concentration on value-for-money healthcare solutions is expected to drive growth within the biosimilar heparins segment going forward into the next few years.

Challenge: Supply Chain Disruptions and Raw Material Availability

Ongoing supply chain disruptions and the availability of raw materials are major challenges that face the heparin market. Heparin is mainly obtained from porcine intestinal mucosa, with China being a key global supplier of pig farming. For example, approximately 80% of global crude heparin comes from China. This supply has been highly volatile in the past due to swine flu and African swine fever that have previously wiped out 50% populations of pigs impacting significantly on world’s supply of heparin. Moreover, recent disruptions in the global supply chain caused by COVID-19 pandemic and geopolitical tensions have complicated matters further. For instance, scarcity of heparin during the pandemic was reported in several countries such as USA and India. One way to mitigate these risks involves finding alternative sources of heparin, improving transparency in the supply chain as well as investing in synthetic methods for making it which is difficult to do.

Although synthetic production of heparins is still at its infancy, there are indications that this could be feasible. Researchers have produced synthetic versions closely resembling natural anticoagulants found in this product for example. Furthermore, some companies in the global heparin market are considering bovine sources as an alternative which could bring about diversification within the supply chain system. Bovine-derived heparins have been given approval by U.S FDA thus minimizing possible disruptions. Additionally, it is vital to improve supply chain transparency. By using blockchain technology we can follow up each unit or verify origin and quality; thereby reducing contamination risk factors associated with production processes involved when manufacturing high-sensitivity substances like heparins. Investments into these areas will be necessary for stabilizing the market for heparins guaranteeing regular supplies of this vital blood thinner drug.

Segmental Analysis 

By Product Type

The global heparin market is commanded by the Low Molecular Weight Heparin (LMWH) segment. Its revenue amounted to US$ 9.84 billion in 2023 alone. There are many reasons for this dominance. Another advantage of LMWHs over UFH is their predictable anticoagulant response thus making them a choice among health care providers. Moreover, they have lower probabilities of causing heparin-induced thrombocytopenia (HIT), which is a life-threatening side effect than other alternatives.

Their greater ease of administration, which usually involves subcutaneous routes and the ability to be treated at home also enhances this popularity further. A considerable proportion of the approximately 10 million DVT incidents worldwide each year are managed with LMWH for instance. This trend in the heparin market will continue as the LMWH segment has been predicted to grow at a CAGR of 4.4% during the forecast period. Prophylaxis and treatment of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) extensively use LMWHs. In America, over six hundred thousand VTE instances are recorded every year where most of them receive treatment with LMWHs while in Europe they are preferred for obstetric patients with about 1 in 1000 pregnancies receiving treatment for thromboprophylaxis. Additionally, some biologics have seen an uptake rate surpassing 50% by LMWHs.

Between 2022 and 2030, the global market for LMWH is expected to grow at a CAGR of 6.7%. This growth indicates that there is an increasing dependence on LMWH as an important drug used in preventing and treating thromboembolic disorders. Besides this, expansion of markets illustrates continuous acceptance and integration of LMWH within hospital or home healthcare settings too.

By Source

The porcine source still remains the top supplier in the heparin market globally with a revenue of US$ 10.65 billion in 2023. Because pigs have a high-quality yield ratio and established extraction processes at low production costs, traditionally, heparin has been sourced from the intestinal mucosa of pigs. China is a major player in this market as it accounts for about 80% of all crude heparin that is produced across the world. Despite challenges such as diseases outbreaks like African swine fever which reduced pig population by up to 50%, porcine-derived heparin remains leading due to its efficacy and cost-effectiveness.

Porcine Source segment is expected to dominate global heparin market during forecast years growing at CAGR of 4.3%. The global Market is anticipated to reach over USD 15.58 billion by 2032 due to increasing cases of cardiovascular diseases and venous thromboembolism (VTE). In US alone, more than six hundred thousand VTE cases are reported annually majority being treated using heparin as an anticoagulant drug. Also rising number of surgeries and dialysis procedures point towards growing demand for heparin worldwide estimated at approximately annual growth rate of 5%.

Attempts are being made to find alternative sources because challenges mentioned above have rendered the porcine source undesirable for some-thing. For example, synthetic variants mimicking natural properties are being developed by researchers in order to make synthetic form of Heparin viable for commercial use. Another possible substitute for bovine-derived Heparin—for diversification purposes—has been approved by U.S FDA as an ingredient in food products manufactured there out of their country’s supplies chain. Nevertheless, nothing seems possible before the viability becomes real so far as this issue continues to be relevant commercially except maybe few countries such those dealing with Porcine which remain primary sources hence stable supply are guaranteed for the long term.

By Application

VTE is the leading application area for the global heparin market, earning US$ 3.29 billion in 2023. VTE, which covers diseases like DVT and PE, poses a considerable threat to world public health. In the US alone, nearly 900k VTE cases occur per year resulting in more than 100k deaths. The increase in sedentary lifestyle and aging coupled with over 650m adults being obese globally has resulted in VTE rising. Heparin dominates this segment because it is a powerful blood thinner that is used to treat and prevent venous thromboembolism (VTE). Heparin use in surgeries has grown much requiring anticoagulant therapy for many of these procedures which accounts for its dominance. Furthermore, dialysis has contributed to the demand as well; approximately three million people are subjected to it worldwide.

The incidence rate of VTE combined with its continuous prevalence and threat to public health will keep the demand for heparin as an anticoagulant at a CAGR of about 4.4% throughout the forecast period. They will be most affected by this group which is expected to grow up until 1.5 billion elderly population all around them by 2050. Hospitalizations due to VTE tend to be extremely numerous, accounting for around one-tenth of hospital deaths as well as about one out ten hospital deaths are associated with VTE.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America continued at the forefront in generating US$ 3.89 billion in the global heparin market in 2023. The region's dominance can be attributed to several reasons. First, this part of the world has a high number of cardiovascular diseases (CVDs) and venous thromboembolism (VTE), two major conditions where heparin plays a central role. It is projected that almost half of all adult Americans – approximately 126 million people – suffer some type of CVD according to the American Heart Association. Moreover, about 900,000 Americans are diagnosed with VTE every year leading to roughly 100,000 deaths. The strong healthcare infrastructure coupled with high expenditure on healthcare promotes these trends in both United States and Canada. In 2023, USA spent $6.4 trillion on health care which accounted for roughly 19.7% of its GDP. Similarly, Canada spends around 11.5% of its GDP on health care amounting to about $344 billion in 2023. This accessibility means that there is early diagnosis and management of diseases requiring use of heparin therefore ensuring that it is demanded for.

North America heparin market has an impressive network of over 88,000 pharmacies and six thousand two hundred ten hospitals in the U.S., as well as more than ten thousand pharmacies and four thousand hospitals in Canada ensuring efficient distribution and availability of heparin.  Additionally, North America enjoys prominence due to the existence of large pharmaceutical firms dealing with heparin such as Pfizer and Baxter among others like them operating within it. Pfizer and Baxter generate $58.5 billion and $14.81 billion revenues respectively in 2023. Thereby, they are contributing immensely towards local economy development while making key strides in production, application, and research related to heparin.

Another aspect which characterizes the regional heparin market is a solid regulatory framework governed by agencies such as the Food and Drug Administration (FDA) which assures heparin products’ efficiency and safety. In 2023, the FDA authorized more than 55 new drugs showing its active participation in maintaining stringent guidelines. This regulatory oversight adds an additional layer of consumer trust and confidence in the products available in this region.

Besides having great regulations, North America is also a center of clinical trials and medical research. In 2023, out of all global pharmaceutical R&D expenditures, US alone accounted for 78% which was $191billion. This commitment to research ensures continuous improvement of heparin products and application techniques. Moreover, there are numerous surgical operations performed at a higher rate that support North American heparin market. Every year over 50 million surgeries are conducted in USA; many require anticoagulant therapy. Furthermore, the aging North American population where more than 54 million citizens have reached age 65 years contributes to increased demand for heparin since they are prone to CVD and VTE.

Top Players in the Global Heparin Market 

• Dr. Reddy’s Laboratories Ltd
• GSK
• Sanofi
• Pfizer, Inc.
• LEO Pharma A/S
• Aspen
• Baxter International, Inc
• Syntex S.A.
• Opocrin S.p.A
• Bioiberica S.A.U.
• B. Braun Medical, Inc.
• Nanjing King-Friend Biochemical Pharmaceutical
• Yantai Dongcheng Biochemicals Co., Ltd.
• Fresenius Kabi
• Other Prominent Players

Market Segmentation Overview:

By Product Type

• Unfractionated Heparin (UFH)
• Low Molecular Weight Heparin (LMWH)
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Others
• Ultra-low Molecular Weight Heparin (ULMWH)

By Source

• Bovine
• Porcine

By Application

• Venous thromboembolism
• Dialysis
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America